芦可替尼用于治疗成人斯蒂尔病并发的难治性巨噬细胞活化综合征。
Ruxolitinib for Refractory Macrophage Activation Syndrome Complicating Adult-Onset Still's Disease.
作者信息
Levy Ofer, Apel Arie, Alhdor Hossam, Mizrachi Avraham, Agmon-Levin Nancy, Koren-Michowitz Maya, Amit-Vazina Mirit
机构信息
Shamir Medical Center, Internal Medicine B, Rheumatology Unit, Zerifin, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Shamir Medical Center, Department of Hematology, Zerifin, Israel.
出版信息
Eur J Rheumatol. 2022 Oct;9(4):217-220. doi: 10.5152/eurjrheum.2022.21064.
Abstract
Macrophage activation syndrome is the most frequent life-threatening complication of adult-onset Still's disease. This is a nearly fatal case of a young patient, which has been refractory to corticoste- roids, anakinra, tocilizumab, cyclosporine A, and etoposide, but eventually responded miraculously to salvage therapy with ruxolitinib. We review recent pertinent data related to the therapeutic value of ruxolitinib for macrophage activation syndrome triggered by adult-onset Still's disease.
摘要
巨噬细胞活化综合征是成人斯蒂尔病最常见的危及生命的并发症。这是一名年轻患者的近乎致命的病例，该病例对皮质类固醇、阿那白滞素、托珠单抗、环孢素A和依托泊苷均无反应，但最终对鲁索替尼挽救治疗产生了奇迹般的反应。我们回顾了与鲁索替尼治疗成人斯蒂尔病引发的巨噬细胞活化综合征的治疗价值相关的近期相关数据。
相似文献
1
Ruxolitinib for Refractory Macrophage Activation Syndrome Complicating Adult-Onset Still's Disease.芦可替尼用于治疗成人斯蒂尔病并发的难治性巨噬细胞活化综合征。
Eur J Rheumatol. 2022 Oct;9(4):217-220. doi: 10.5152/eurjrheum.2022.21064.
2
Efficacy of high-dose anakinra in refractory macrophage activation syndrome in adult-onset Still's disease: when dosage matters in overcoming secondary therapy resistance.大剂量阿那白滞素治疗成人斯蒂尔病难治性巨噬细胞活化综合征的疗效：剂量在克服二线治疗耐药中的重要性。
Ther Adv Musculoskelet Dis. 2020 Nov 24;12:1759720X20974858. doi: 10.1177/1759720X20974858. eCollection 2020.
3
Macrophage activation syndrome complicating adult onset Still's disease: A single center case series and comparison with literature.巨噬细胞活化综合征并发成人斯蒂尔病：单中心病例系列研究及与文献的比较。
Semin Arthritis Rheum. 2016 Jun;45(6):711-6. doi: 10.1016/j.semarthrit.2015.11.002. Epub 2015 Nov 10.
4
A Case of Macrophage Activation Syndrome During the Treatment of Adult-onset Still's Disease With Tocilizumab.一例使用托珠单抗治疗成人斯蒂尔病期间发生巨噬细胞活化综合征的病例。
J Rheum Dis. 2022 Apr 1;29(2):123-128. doi: 10.4078/jrd.2022.29.2.123.
5
Successful use of short-term add-on tocilizumab for refractory adult-onset still's disease with macrophage activation syndrome despite treatment with high-dose glucocorticoids, cyclosporine, and etoposide.尽管使用了大剂量糖皮质激素、环孢素和依托泊苷治疗，但短期加用地塞米松治疗难治性成人斯蒂尔病伴巨噬细胞活化综合征仍获得成功。
Mod Rheumatol Case Rep. 2020 Jul;4(2):202-207. doi: 10.1080/24725625.2020.1741073. Epub 2020 Mar 23.
6
Reactive macrophage activation syndrome possibly triggered by canakinumab in a patient with adult-onset Still's disease.可能由康那奴单抗引发的成年Still 病患者反应性巨噬细胞活化综合征。
Joint Bone Spine. 2013 Dec;80(6):653-5. doi: 10.1016/j.jbspin.2013.04.011. Epub 2013 Jun 7.
7
Macrophage Activation Syndrome Associated with Adult-Onset Still's Disease Successfully Treated with Anakinra.托珠单抗成功治疗与成人斯蒂尔病相关的巨噬细胞活化综合征。
Case Rep Rheumatol. 2016;2016:3717392. doi: 10.1155/2016/3717392. Epub 2016 Oct 12.
8
Rescued from desperation: adult-onset Still's disease with life-threatening interstitial lung disease and macrophage activation : Successful treatment by Tocilizumab.从绝望中拯救：成人斯蒂尔病伴危及生命的间质性肺病和巨噬细胞活化：托珠单抗成功治疗
Z Rheumatol. 2022 May;81(4):335-338. doi: 10.1007/s00393-021-01063-7. Epub 2021 Aug 10.
9
Interleukin-6 inhibition: a therapeutic strategy for the management of adult-onset Still's disease.白细胞介素-6抑制：一种治疗成人斯蒂尔病的策略。
Expert Opin Biol Ther. 2022 Jan;22(1):79-85. doi: 10.1080/14712598.2021.1942832. Epub 2021 Jun 24.
10
Short-term, low-dose etoposide in refractory adult-onset Still's disease-associated macrophage activation syndrome.短期、低剂量依托泊苷治疗难治性成人斯蒂尔病相关巨噬细胞活化综合征。
Clin Rheumatol. 2022 Sep;41(9):2817-2823. doi: 10.1007/s10067-022-06184-1. Epub 2022 May 19.
引用本文的文献
1
Efficacy and safety of ruxolitinib in adult patients with refractory rheumatic disease-associated macrophage activation syndrome.鲁索替尼治疗难治性风湿性疾病相关巨噬细胞活化综合征成年患者的疗效和安全性。
Front Immunol. 2025 Jun 26;16:1604648. doi: 10.3389/fimmu.2025.1604648. eCollection 2025.
2
Macrophage activation syndrome-associated adult onset Still disease treatment: a scoping review of case reports and case series.巨噬细胞活化综合征相关的成人斯蒂尔病治疗：病例报告和病例系列的范围综述
Proc (Bayl Univ Med Cent). 2025 Apr 1;38(4):499-511. doi: 10.1080/08998280.2025.2482315. eCollection 2025.
3
Efficacy and safety of therapies for Still's disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR/PReS guidelines for the management of Still's disease.Still 病和巨噬细胞活化综合征（MAS）治疗的疗效和安全性：一项系统评价，为 EULAR/PReS Still 病管理指南提供信息。
Ann Rheum Dis. 2024 Nov 14;83(12):1731-1747. doi: 10.1136/ard-2024-225854.
4
JAK Inhibitors in Cytokine Storm Syndromes.JAK 抑制剂在细胞因子风暴综合征中的应用。
Adv Exp Med Biol. 2024;1448:583-600. doi: 10.1007/978-3-031-59815-9_39.
5
Immunopathology of and potential therapeutics for secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome: a translational perspective.继发性噬血细胞性淋巴组织细胞增多症/巨噬细胞活化综合征的免疫病理学及潜在治疗策略：转化医学视角
Exp Mol Med. 2024 Mar;56(3):559-569. doi: 10.1038/s12276-024-01182-6. Epub 2024 Mar 6.
6
Advances in attractive therapeutic approach for macrophage activation syndrome in COVID-19.COVID-19 中巨噬细胞活化综合征有吸引力的治疗方法进展。
Front Immunol. 2023 Jul 6;14:1200289. doi: 10.3389/fimmu.2023.1200289. eCollection 2023.
7
Rare complications of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: Time to nip them in the bud.抗黑色素瘤分化相关基因 5 抗体阳性皮肌炎的罕见并发症：防微杜渐。
Front Immunol. 2022 Oct 6;13:1009546. doi: 10.3389/fimmu.2022.1009546. eCollection 2022.
本文引用的文献
1
Ruxolitinib combined with doxorubicin, etoposide, and dexamethasone for the treatment of the lymphoma-associated hemophagocytic syndrome.芦可替尼联合多柔比星、依托泊苷和地塞米松治疗淋巴瘤相关噬血细胞综合征。
J Cancer Res Clin Oncol. 2020 Nov;146(11):3063-3074. doi: 10.1007/s00432-020-03301-y. Epub 2020 Jul 2.
2
Tofacitinib in refractory adult-onset Still's disease: 14 cases from a single centre in China.托法替布治疗难治性成人斯蒂尔病：来自中国单中心的14例病例
Ann Rheum Dis. 2020 Jun;79(6):842-844. doi: 10.1136/annrheumdis-2019-216699. Epub 2020 Feb 20.
3
Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial.芦可替尼治疗成人继发性噬血细胞性淋巴组织细胞增生症：一项开放标签、单中心的试点试验。
Lancet Haematol. 2019 Dec;6(12):e630-e637. doi: 10.1016/S2352-3026(19)30156-5. Epub 2019 Sep 16.
4
Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis.芦可替尼用于难治性/复发性噬血细胞性淋巴组织细胞增生症
Haematologica. 2020 May;105(5):e210-e212. doi: 10.3324/haematol.2019.222471. Epub 2019 Sep 12.
5
Macrophage activation syndrome complicating rheumatic diseases in adults: case-based review.成人风湿性疾病并发巨噬细胞活化综合征：基于病例的综述
Rheumatol Int. 2020 Apr;40(4):663-669. doi: 10.1007/s00296-019-04393-7. Epub 2019 Jul 31.
6
Calming the storm in HLH.平息噬血细胞性淋巴组织细胞增生症中的风暴。
Blood. 2019 Jul 11;134(2):103-104. doi: 10.1182/blood.2019001333.
7
Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis.鲁索利替尼在噬血细胞性淋巴组织细胞增生症小鼠模型中的作用机制。
Blood. 2019 Jul 11;134(2):147-159. doi: 10.1182/blood.2019000761. Epub 2019 Apr 23.
8
Recommendations for the management of hemophagocytic lymphohistiocytosis in adults.成人噬血细胞性淋巴组织细胞增生症的治疗建议。
Blood. 2019 Jun 6;133(23):2465-2477. doi: 10.1182/blood.2018894618. Epub 2019 Apr 16.
9
Treatment of refractory adult onset Still's disease with combination anakinra and baricitinib therapy.联合使用阿那白滞素和巴瑞替尼治疗难治性成人斯蒂尔病。
Rheumatology (Oxford). 2019 Apr 1;58(4):736-737. doi: 10.1093/rheumatology/key414.
10
Complications of adult-onset Still's disease and their management.成人斯蒂尔病的并发症及其处理。
Expert Rev Clin Immunol. 2018 May;14(5):351-365. doi: 10.1080/1744666X.2018.1465821. Epub 2018 Apr 26.
Zotero 插件